One Capital Management LLC Raises Stock Holdings in Halozyme Therapeutics, Inc. $HALO

One Capital Management LLC grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 39.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 46,806 shares of the biopharmaceutical company’s stock after purchasing an additional 13,248 shares during the quarter. One Capital Management LLC’s holdings in Halozyme Therapeutics were worth $3,150,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Clark Capital Management Group Inc. increased its position in shares of Halozyme Therapeutics by 14.4% during the 3rd quarter. Clark Capital Management Group Inc. now owns 202,965 shares of the biopharmaceutical company’s stock valued at $14,885,000 after purchasing an additional 25,582 shares during the last quarter. Intech Investment Management LLC increased its position in shares of Halozyme Therapeutics by 46.0% during the 3rd quarter. Intech Investment Management LLC now owns 148,667 shares of the biopharmaceutical company’s stock valued at $10,903,000 after purchasing an additional 46,850 shares during the last quarter. Allworth Financial LP grew its stake in shares of Halozyme Therapeutics by 322.5% during the 3rd quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock valued at $2,914,000 after acquiring an additional 30,331 shares during the period. ING Groep NV bought a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at approximately $6,652,000. Finally, Element Squared LLC bought a new position in shares of Halozyme Therapeutics during the 4th quarter valued at approximately $1,193,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

HALO stock opened at $66.28 on Wednesday. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The business’s fifty day simple moving average is $66.24 and its two-hundred day simple moving average is $68.75. Halozyme Therapeutics, Inc. has a twelve month low of $51.06 and a twelve month high of $82.22. The firm has a market cap of $7.86 billion, a price-to-earnings ratio of 23.84, a PEG ratio of 0.28 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same quarter last year, the firm posted $1.11 earnings per share. The business’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Analysts predict that Halozyme Therapeutics, Inc. will post 7.6 earnings per share for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $69.19, for a total value of $691,900.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at $53,122,698.20. This trade represents a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total value of $599,087.48. Following the completion of the sale, the chief operating officer owned 7,055 shares in the company, valued at approximately $477,200.20. The trade was a 55.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 92,107 shares of company stock worth $6,212,534 over the last quarter. Company insiders own 2.50% of the company’s stock.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of recent research reports. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. HC Wainwright boosted their price objective on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Benchmark boosted their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Finally, Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $80.67.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.